BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX, Inc., the leader in NGS-based gene fusion detection, has announced an agreement with GenomOncology, Inc., the leader in NGS variant interpretation, to co-market Archer’s NGS assays and GenomOncology’s data interpretation software for somatic mutation detection and reporting. Under terms of the agreement, GenomOncology’s GO Clinical Workbench™ will now support interpretation of multiple ArcherDX assays, including ALK, RET, ROS1, Solid Tumor, and Comprehensive Thyroid and Lung (CTL) panels.
“Using Archer’s assays with GenomOncology’s reporting software will be of great benefit to molecular laboratories,” said Jason Myers, CEO of ArcherDX. “Archer’s assays are comprehensive by design, and our workflow makes it easy to generate a list of variants from low-input FFPE samples.”
Jill Stefanelli, Director of Pharma Business Development at ArcherDX, elaborated. “GenomOncology’s GO Clinical Workbench will empower labs of all sizes to run and annotate ArcherDX NGS assays, from both RNA and DNA aberrations. Furthermore, inclusion of a rules-based reporting pipeline provides a much-needed step towards standardization of NGS methodologies.”
“Archer’s assays are highly regarded by molecular pathologists and researchers alike,” said Manuel Glynias, CEO at GenomOncology. “Through this partnership, the companies will together facilitate the most streamlined and complete testing and decision support solutions for our clients.”
The incorporation of GenomOncology’s GO Clinical Workbench into the workflow will allow customers to move directly from a list of variants to a knowledge-driven interpretive report, enabling laboratories of all sizes to get meaningful results from targeted NGS assays.
Archer VariantPlex™ and FusionPlex™ assays are purpose-built to detect oncogenic fusions, RNA abundance, copy number variations (CNVs), single nucleotide variants (SNVs) and insertions/deletions (indels) from FFPE samples. Archer’s Solid Tumor and Comprehensive Thyroid and Lung (CTL) assays combine both RNA- and DNA-based sequencing assays into a single workflow, allowing comprehensive profiling of multiple tumor types in a rapid, economical manner.
The GO Clinical Workbench is part of the The GO Precision Medicine Portfolio™, a full suite of tools designed to help healthcare institutions implement, perform, and maximize the benefits of precision medicine. The tools are installed behind the institution’s firewall and are configured to each laboratory’s specific needs.
ArcherDX addresses the bottlenecks associated with using next-generation sequencing in translational research by offering a robust platform for targeted sequencing applications.
By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, ArcherDX technology generates highly enriched sequencing libraries to detect gene fusions, SNVs, indels and CNVs. Complemented by the Archer suite of bioinformatics software and readily accessible reports, ArcherDX technology dramatically enhances complex mutation identification and discovery.
ArcherDX is headquartered in Boulder, Colo., and maintains manufacturing operations in Beverly, Mass. www.archerdx.com
Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.
GenomOncology is a healthcare technology company enabling precision medicine by transforming genomic data into actionable information. The GO Precision Medicine Portfolio™ is trusted by molecular pathologists and medical geneticists for streamlined development and production of knowledge- and guideline-driven cancer and hereditary disease tests. GenomOncology’s technology allows multiple modes of genetic analysis to fuel integrated clinical decision support and research built on accumulating experience. Learn more at www.genomoncology.com.